Biohaven closes $200M public offering at $7.50 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at Morgan Stanley
November 17, 2025 7:38 AM ESTMorgan Stanley analyst Terence Flynn lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $26.00 (from $54.00) while maintaining a Overweight rating.
The analyst comments "BHVN announced on 10/4 that it received a Complete Response Letter (CRL) from the FDA regarding its NDA for... More
